$0.62
8.56% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US74365N1037
Symbol
PTIX

Protagenic Therapeutics Inc Stock price

$0.62
+0.02 3.32% 1M
-1.20 65.94% 6M
-0.37 37.38% YTD
-1.15 64.98% 1Y
-7.26 92.13% 3Y
-4.98 88.93% 5Y
-290.10 99.79% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.05 8.56%
ISIN
US74365N1037
Symbol
PTIX

Key metrics

Market capitalization $2.55m
Enterprise Value $1.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.22
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-6.05m
Free Cash Flow (TTM) Free Cash Flow $-5.16m
Cash position $920.00k
EPS (TTM) EPS $-1.46
Short interest 10.67%
Show more

Is Protagenic Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Protagenic Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Protagenic Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Protagenic Therapeutics Inc:

Buy
100%

Financial data from Protagenic Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
-
-
-0.05 -0.05
-
-
- Selling and Administrative Expenses 1.13 1.13
26% 26%
-
- Research and Development Expense 4.81 4.81
148% 148%
-
-6 -6
73% 73%
-
- Depreciation and Amortization 0.05 0.05
-
-
EBIT (Operating Income) EBIT -6.05 -6.05
75% 75%
-
Net Profit -6.40 -6.40
86% 86%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protagenic Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagenic Therapeutics Inc Stock News

Neutral
Accesswire
5 months ago
NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. This marks a significant milestone with the enrollment of 30 subjects acro...
Neutral
Accesswire
5 months ago
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a talk on PT00114, the company's promising new drug candidate, at the Peptide Based Therapeutic Summit in Bosto...
Neutral
Seeking Alpha
6 months ago
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
More Protagenic Therapeutics Inc News

Company Profile

Protagenic Therapeutics, Inc. is a biotechnology company, which engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Head office United States
Employees 3
Founded 1994
Website www.protagenic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today